TSH Receptor Chimera Autoantibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting autoimmune antibodies against the TSH receptor are time-consuming, unreliable, and unable to distinguish between stimulating, blocking, and neutral antibodies, with existing assays suffering from high unspecific binding and instability of TSH receptor chimeras.
Innovation Solution
A method using TSH receptor chimeras with sequences replaced by those from other G-protein-coupled receptors to prevent binding of specific autoantibodies, combined with C-terminal modifications and labeled secondary antibodies for enhanced specificity and sensitivity, allowing for differential determination of autoantibodies on a solid phase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If TSH receptor chimeras are used for detection, then measurement precision is improved, but device complexity increases due to centrifugation separation requirements
Solution Approach 1:
The patent extracts and removes the centrifugation separation step from the assay procedure. Instead of using complete TSH receptor chimeras that require centrifugation to separate bound from free receptor, the invention uses truncated TSH receptor extracellular domains that remain stable and functional without requiring such complex separation procedures, thereby simplifying the device while maintaining detection precision
Solution Approach 2:
The patent employs stable, truncated TSH receptor extracellular domains that can be used directly without requiring complex stabilization procedures or ice bath conditions. These simplified receptor fragments serve as disposable, stable binding reagents that eliminate the need for complex centrifugation-based separation systems
2Measurement precision
If complete TSH receptor chimeras are used, then measurement precision is improved, but stability deteriorates requiring ice bath or 4°C storage
Solution Approach 1:
The patent extracts only the stable extracellular domain (amino acids 1-261) of the TSH receptor, removing the unstable transmembrane and intracellular regions. This truncated extracellular domain maintains high binding specificity for autoantibodies while exhibiting superior thermal and storage stability, eliminating the requirement for ice bath or 4°C storage conditions
Solution Approach 2:
The patent changes the structural parameters of the TSH receptor by truncating it to include only the extracellular domain (amino acids 1-261). This parameter change fundamentally improves stability while preserving measurement precision, as the extracellular domain contains all necessary epitopes for autoantibody binding without the instability introduced by full-length receptor structures
3Ease of manufacture
If first generation in-vitro methods with pork thyroid gland membrane are used, then ease of manufacture is improved, but measurement precision deteriorates due to inability to distinguish antibody types
Solution Approach 1:
The patent applies local quality by creating different TSH receptor chimera variants with specific epitope modifications. Each chimera type is designed with distinct characteristics that enable selective binding to stimulating, blocking, or neutral autoantibodies, allowing differentiation while maintaining the simplicity of an in-vitro assay format
Solution Approach 2:
The patent introduces TSH receptor chimera variants as intermediary binding reagents that mediate the differentiation between antibody types. These chimeras serve as specific mediators that bind preferentially to different autoantibody types, enabling precise classification while keeping the overall assay procedure simple and manufacturable
4Ease of operation
If sandwich technique is used for detection, then ease of operation is improved, but measurement precision deteriorates due to high unspecific binding
Solution Approach 1:
The patent extracts and eliminates the problematic unspecific binding component from the sandwich technique by using truncated TSH receptor extracellular domains instead of complete chimeras. This extraction removes the source of unspecific binding while preserving the specific epitope regions that bind autoantibodies, thereby maintaining ease of operation while improving measurement precision
Solution Approach 2:
The patent uses stable, truncated TSH receptor extracellular domains as simplified binding reagents that eliminate unspecific binding problems. These truncated receptors serve as clean, specific binding agents that maintain ease of operation through simple incubation procedures while achieving high specific binding without the artifacts of complete chimera-based sandwich techniques
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method improves the accuracy and expressiveness of TSH receptor autoantibody detection, reducing unspecific binding and increasing stability, enabling automated detection with high precision and sensitivity.
Implementation Method 1
an autoimmune antibody with an antigen-binding fragment binds to the first TSH receptor chimera
Implementation Method 2
a labeled secondary antibody directed against the modified C-terminal epitope of the second receptor chimera, wherein this antibody binds to the modified C-terminal epitope of the second TSH receptor chimera, and triggers a detectable event
Data Source
AI summary
Methods are described for detection of autoimmune antibodies against the TSH receptor using TSH receptor chimeras, which preferably only contain the extracellular portion of the TSH wild type receptor modified as chimera, and are modified by highly immunogenic peptide residues or by enzymes suitable for detection, wherein the determination methods described allow simple detection of stimulating, blocking and neutral autoimmune antibodies.